New 5-HT2C receptor agonists

Bibliography

• JENCK F, BOS M, WICHMANN J et al: The role of 5-HT2c receptors in affective disorders. Expert Opin. Invest. Drugs (1998) 7:1587–1599.
   PubMedGoogle Scholar
• BUTINI S, CAMPIANI G, DE ANGELIS M et al.: Novel antipsychotic agents: recent advances in the drug treatment of schizophrenia. Expert Opin. The]: Patents(2003) 13:425–448.
   Google Scholar
• ROTH BL, SHAPIRO DA: Insights into structure and function of 5-HT2 family serotonin receptors reveal novel strategies for therapeutic target development. Expert Opin. The]: Targets(2001) 5:685–695.
   Google Scholar
• SPANSWICK D, LEE K: Emerging antiobesity drugs. Expert Opin. Emerging Drugs (2003) 8:217–237.
   PubMedGoogle Scholar
• CHAKI S, NAKAZATO A: Recent advances in feeding suppressing agents: potential therapeutic strategy for the treatment of obesity. Expert Opin. The]: Patents (2001) 11:1677–1692.
   Google Scholar
• SPIGSET O, HAGG S: Therapeutic approaches to bulimia nervosa. Expert Opin. Ther. Patents (2001) 11:463–477.
   Web of Science ®Google Scholar
• CARPINO PA: Patent focus on new antiobesity agents: September 1999 - February 2000. Expert Opin. The]: Patents (2000) 10:819–831.
   Google Scholar
• HOYER D, CLARKE DE, FOZARD JR et al.: The IUPHAR classification of receptors of 5-hydroxytryptamine (serotonin). Pharmacol Rev (1994) 46:157–203.
   PubMed Web of Science ®Google Scholar
• SAXENA PR: Serotonin receptors: subtypes, functional responses, and therapeutic relevance. Pharmacol Ther. (1995) 66:339–368.
   PubMed Web of Science ®Google Scholar
• PASQUALETTI M, ORI M, CASTAGNA M, MARAZZITI D, CASSANO GB, NARDI I: Distribution and cellular localization of the serotonin Type 2C receptor messenger RNA in human brain. Neuroscience (1999) 92:601–611.
   PubMed Web of Science ®Google Scholar
• BICKERDIKE MJ: 5-HT2c receptor agonists as potential drugs for the treatment of obesity. Carr. Top. Med. Chem. (2003) 3:885–897.
   PubMed Web of Science ®Google Scholar
• •This review provides an excellent discussion of the potential utility of 5-HT2c agonists in antiobesity therapy.
   Google Scholar
• ISAAC M: The 5-HT2c receptor as a22. potential therapeutic target for the design of antiobesity and antiepileptic drugs. Drugs Future (2001) 26:383–393.
   Google Scholar
• •This review provides an excellent23.discussion of the potential utility of 5-HT2c agonists in antiepileptic therapy.
   Google Scholar
• FITZGERALD LW, ENNIS MD: 5-HT2c receptor modulators: progress in development of new CNS medicines. Ann. Rep. Med. Chem. (2002) 37:21–30.
   Google Scholar
• BARNES NM, SHARP T: A review of• central 5-HT receptors and their function. Neuropharmacology (1999) 38:1083–1152.
   PubMed Web of Science ®Google Scholar
• BURNS CM, CHU H, RUETER SM24. et al.: Regulation of serotonin-2C receptor G protein coupling by RNA editing. Nature (1997) 387:303–308.
   Google Scholar
• KENNETT GA: 5-HT1c receptors and their therapeutic relevance. Curt: Opin. Invest. Drugs (1993) 2:317-362.25.
   Google Scholar
• •This older review discusses several potential therapeutic applications for 5-HT2c ligands with useful citations.
   Google Scholar
• TECOTT L, SUN LM, AKANA SF et al:26. Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature (1995) 374:542–546.
   Google Scholar
• ••This paper is the initial publication on the•5-HT2c knockout mouse.
   Google Scholar
• PORTER RHP, BENWELL KR, LAMB H et al.: Functional characterization of agonists at recombinant human 5-HT, 5-HT2B, and 5-HT2c receptors in CHO-Kl cells. Br. Pharmacol (1999) 128:13–20.
   Google Scholar
• ••This paper provides robust in vitro28.characterisation data for a number of 5-HT2 agonists that have been used as pharmacological tools.
   Google Scholar
• KENNETT GA, WOOD MD, BRIGHT F et al.: SB-242084, a selective and brain- penetrant 5-HT2c receptor antagonist.29.Neuropharmacology (1997) 36:609–620.
   Google Scholar
• HEWITT KN, LEE MD, DOURISH CT, CLIFTON PG: Serotonin 2C receptor agonists and the behavioural satiety30.sequence in mice. Pharmacol Biochem. Behav. (2002) 71:691–700.
   PubMed Web of Science ®Google Scholar
• VICKERS SP, DOURISH CT, KENNETT GA: Evidence that hypophagia31.induced by cifenfluramine and cknorfenfluramine in the rat is mediated by 5-HT2c receptors. Neuropharmacology•(2001) 41:200–209.
   Google Scholar
• GALLANT DM, BISHOP MP, BISHOP G et al.: U-22394A: a controlled evaluation in chronic schizophrenic patients. Carr. The]: Res. (1967) 9:579–581.
   Google Scholar
• MCCALL, RB, FRANKLIN SR, HYSLOP DK et al: PNU-22394, a 5-HT2c receptor agonist, reduces feeding in rodents and produces weight loss in humans. 31st Annual Meeting of the Socien, for Neuroscience. San Diego, USA (10–15 November, 2001).
   Google Scholar
• •The previous two references describe human clinical trial results with a 5-HT2c agonist.
   Google Scholar
• VICKERS SP, EASTON N, WEBSTER LJ et al.: Oral administration of the 5-HT2c receptor agonist, mCPP, reduces body weight gain in rats over 28 days as a result of maintained hypophagia. Psychopharmacology (2003) 167:274–280.
   Google Scholar
• HEISLER LK, COWLEY MA, TECOTT LH et al.: Activation of central melanocortin pathways by fenfluramine. Science (2002) 297:609–611.
   PubMed Web of Science ®Google Scholar
• MARTIN JR, BOS M, JENCK F et al.: 5-HT2c receptor agonists: pharmacological characteristics and therapeutic potential. Pharmacol Exp. Ther. (1998) 286:913–924.
   PubMed Web of Science ®Google Scholar
• •This paper discusses the effects of 5-HT2c agonists in several in vivo models that evaluate CNS activity.
   Google Scholar
• NIC DHONNCHADHA BA, BOURIN M, HASCOET M: Amdolytic-like effects of 5-HT2 ligands on three mouse models of anxiety. Behav. Brain Res. (2003) 40:203–214.
   Google Scholar
• ENNIS MD, HOFMANN RB, GHAZAL NB et al.: 2,3,4,5-Tetrahydro-and 2,3,4,5,11,11a-hexahydro-1H-[1,4]diazepino [1,7 - indoles: new templates for 5-HT2c agonists. Bioorg. Med. Chem. Lett. (2003) 13:2369–2373.
   PubMed Web of Science ®Google Scholar
• KENNETT G, LIGHTOWLER S, TRAIL B et al.: Effects of Ro 60-0175, a 5-HT2c receptor agonist, in three animal models of anxiety. Ear: Pharmacol (2000) 387:197–204.
   Google Scholar
• CRYAN JF, LUCKI I: Antidepressant-like behavioral effects mediated by 5-hydroxytryptamine2c receptors. I Pharmacol Exp. Thec (2000) 295:1120–1126.
   PubMed Web of Science ®Google Scholar
• LEYSEN DCM: Selective 5-HT2c agonists as potential antidepressants. IDrugs (1999) 2:109–120.
   Google Scholar
• •This paper describes human clinical trial results with a 5-HT2c agonist.
   Google Scholar
• MOREAU JL, BOS M, JENCK F et al: 5-HT2c receptor agonists exhibit antidepressant-like properties in the anhedonia model of depression in rats. Eur: Neuropsychopharmacol (1996) 6:169–175.
   PubMed Web of Science ®Google Scholar
• MARSDEN CA, STANFORD SC: CNS drugs III: psychotherapeutics. Expert Opin. Invest. Drugs (2000) 9:1923–1929.
   PubMedGoogle Scholar
• CHOU-GREEN JM, HOLSCHER TD, DALLMAN ME AKANA SF: Compulsive behavior in the 5-HT2c receptor knockout mouse. Physiol Behav. (2003) 78:641–649.
   Google Scholar
• ANDERSSON K-E: Pharmacology of penile erection. Pharmacol Rev (2001) 53:417–450.
   Google Scholar
• MILLAN MJ, PEGLION JL, LAVIELLE G, PERRIN-MONNEYRON S: 5-HT2c receptors mediate penile erections in rats: actions of novel and selective agonists and antagonists. Eur: Pharmacol (1997) 325:9–12.
   PubMedGoogle Scholar
• SZELE FG, MURPHY DL, GARRICK NA: Effects of fenfluramine, m-chlorophenylpiperazine, and other serotonin-related agonists and antagonists on penile erections in non-human primates. Life Sci. (1988) 43:1297–1303.
   PubMedGoogle Scholar
• POMERANTZ SM: 5-HT1A and 5-HTicm receptor agonists produce reciprocal effects on male sexual behavior of rhesus monkeys. Eur.j Pharmacol (1993) 243:227–234.
   PubMed Web of Science ®Google Scholar
• UPTON N, STEANT, MIDDLEMISS D et al.: Studies on the role of 5-HT2c and 5-HT2B receptors in regulating generalised seizure threshold in rodents. Eur: Pharmacol (1998) 359:33–40.
   Google Scholar
• ARJONA AA, POOLER AM, LEE RK, WURTMAN RJ: Effect of a 5-HT2c serotonin agonist, dexnorfenfluramine, on amyloid precursor protein metabolism in guinea pigs. Brain Res. (2002) 951:135–140.
   PubMed Web of Science ®Google Scholar
• DE GROAT WC: Influence of central serotonergic mechanisms on lower urinary tract function. Urology (2002) 59\(Supp1.5A):30–36.
   Google Scholar
• ANDERSSON K-E: Treatment of the overactive bladder: possible central nervous system drug targets. Urology (2002) 59(Supp15A):18–24.
   Google Scholar
• STEERS WD, ALBO M, VAN ASSELT E: Effects of serotonergic agonists on micturition and sexual function in the rat. Drug Dev. Res. (1992) 27:361–375.
   Google Scholar
• STEERS WD, DE GROAT WC: Effects of m-chlorophenylpiperazine on penile and bladder function in rats. Am. I Physiol (1989): 257:R1441–R1449.
   Google Scholar
• BERENDSEN HHG: The role of serotoninin hot flushes. Maturitas (2000) 36:155–164.
   Google Scholar
• BERENDSEN HHG: Hot flushes and serotonin. I Br. Menopause Soc. (2002) 8:30–34.
   Google Scholar
• STEARNS V, BEEBE KL, IYENGAR M, DUBE E: Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA (2003) 289:2827–2834.
   PubMed Web of Science ®Google Scholar
• PLOUFFE L Jr, TROTT EA, LARGOZA M, HANSEN KA: An open trial of sertraline for menopausal hot flushes: potential involvement of serotonin in vasomotor instability. Del. Med. J. (1997) 69:481–482.
   Google Scholar
• GROTTICK AJ, FLETCHER PJ, HIGGINS GA: Studies to investigate the role of 5-HT2c receptors on cocaine- and food-maintained behavior. Pharmacol Exp. Ther. (2000) 295:1183–1191.
   PubMed Web of Science ®Google Scholar
• ROCHA BA, GOULDING EH, O'DELL LE et al.: Enhanced locomotor, reinforcing, and neurochemical effects of cocaine in serotonin 5-hydroxytryptamine2 receptor mutant mice. Neurosci (2002) 22:10039–10045.
   Google Scholar
• TOMKINS DM, JOHARCHI N, TAMPAKERAS JR et al: An investigation of the role of 5-HT2c receptors in modifying ethanol self-administration behaviour. Pharmacol Biochem. Behav. (2002) 71:735–744.
   Google Scholar
• GROTTICK AJ, CORRIGAL WA, HIGGINS GA: Activation of 5-HT2c receptors reduces the locomotor and rewarding effects of nicotine. Psychopharmacology (Berl). (2001) 157:292–298.
   PubMed Web of Science ®Google Scholar
• PIESLA MJ, COMERY TA, BRENNAN JA et al.: Atypical antipsychotic-like effects of 5-HT2c agonists. Schizophrenia Res. (2001) 49(Sp.Iss.SI Suppl.):95.
   Google Scholar
• MAUBACH K: Psychiatric drug discovery and development. Expert Opin. Invest. Drugs (2003) 12:1571–1575.
   PubMedGoogle Scholar
• BOS M, JENCK F, MARTIN JR et al.: Novel agonists of 5HT2c receptors. Synthesis and biological evaluation of substituted 2-(indol 1 yl) 1 methylethylamines and 2- (indeno [1,2-blpyrrol-1-y9-1-methylethylamines. Improved therapeutics for obsessive compulsive disorder. J. Med. Chem. (1997) 40:2762–2769.
   Google Scholar
• ROTH BL, WILLINS DL, KRISTIANSEN K, KROEZE WK: 5-Hydroxytryptamine2 family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2c): where structure meets function. Pharmacol Ther. (1998) 79:231–257.
   PubMed Web of Science ®Google Scholar
• AGHAJANIAN GK, MAREK GJ: Serotonin, via 5 -HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release. Brain Res. (1999) 825:161–171.
   PubMed Web of Science ®Google Scholar
• KIHARA H, HIROSE K, KOGANEI H et al: AT-1015, a novel serotonin (5-HT)2 receptor antagonist, blocks vascular and platelet 5-HT2A receptors and prevents the laurate-induced peripheral vascular lesion in rats. I Cardiovasc. Pharmacol (2000) 35:523–530.
   PubMed Web of Science ®Google Scholar
• LAUNAYJM, HERVE P, PEOC'H K et al:Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat. Med. (2002) 8:1129–1135.
   Google Scholar
• FITZGERALD LW, BURN TC, BROWN BS et al.: Possible role of valvular serotonin 5-HT2B receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol (2000) 57:75–81.
   PubMed Web of Science ®Google Scholar
• ROTHMAN RB, BAUMANN MH, SAVAGE JE et al.: Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation (2000) 102:2836–2841.
   PubMed Web of Science ®Google Scholar
• SETOLA V, HUFEISEN SJ, GRANDE-ALLEN KJ et al: 3, 4-Methylenedioxymethamphetamine (MDMA, 'ecstasy') induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. MM. Pharmacol (2003) 63:1223–1229.
   PubMed Web of Science ®Google Scholar
• LEYSEN D, KELDER J: Ligands for the 5-HT 2c receptor as potential antidepressants and anxiolytics. In: Trends in Drug Research II Van Der Groot H (Ed.), Elsevier, Amsterdam (1999):49–61.
   Google Scholar
• NICHOLS DE: Studies of the relationship between molecular structure and hallucinogenic activity. Pharmacol Biochem. Behav (1986) 24:335–340.
   Google Scholar
• GLENNON RA, ISMAIEL AM, CHAURASIA C et al.: 5-HTID serotonin receptors: results of a structure-affinity investigation. Drug Dev. Res. (1991) 22:25–36.
   Web of Science ®Google Scholar
• TOMASZEWSKI Z, JOHNSON MP, HUANG X, NICHOLS DE: Benzofuran bioisosteres of hallucinogenic tryptamines. Med. Chem. (1992) 35:2061–2064.
   Google Scholar
• NICHOLS DE, LLOYD DH, JOHNSON MP, HOFFMAN AJ: Synthesis and serotonin receptor affinities of a series of enantiomers of a-methyltryptamines: evidence for the binding conformation of tryptamines at serotonin 5-HT1g receptors. .1. Med. Chem. (1988) 31:1406–1412.
   PubMed Web of Science ®Google Scholar
• ISAAC M, SLASSI A, O'BRIEN A et al:Pyrrolo [3, 2, 1-1/1 quinoline derivatives, a 5HT2c receptor agonist with selectivity over the 5HT2A receptor: potential therapeutic applications for epilepsy and obesity. Bioorg. Med. Chem. Lett. (2000) 10:919–921.
   Google Scholar
• GLENNON RA, JACYNO JM, YOUNG R et al.: Synthesis and evaluation of a novel series of NAT-dimethylisotryptamines. I Med. Chem. (1984) 27:41–45.
   PubMedGoogle Scholar
• •This paper provides an early example of the isotryptarnine strategy for 5-HT ligands.
   Google Scholar
• CLIFTON PG, LEE MD, DOURISH CT: Similarities in the action of Ro 60-0175, a 5-HT2c receptor agonist and cifenfluramine on feeding patterns in the rat. Psychopharmacology (Berl) (2000) 152:256–267.
   PubMed Web of Science ®Google Scholar
• DAWSON CE, ADAMS DR, BENTLEY JM et al: Indazoles as selective 5-HT2c receptor agonists for the treatment of obesity. Abstracts of Papers, 224nd ACS National Meeting, Boston, MA (18–22 August, 2002).
   Google Scholar
• SHIMADA I, MAENO K, KAZUTA K et al.: Synthesis and structure-activity relationships of a series of substituted 2- (1H-furo [2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2c receptor agonists. Abstracts of Paper s 224nd ACS National Meeting. Boston, MA (18–22 August, 2002).
   Google Scholar
• DOURISH C: New developments in controlling eating and body weight gain using selective 5HT2c agonists. SMI Conference on Obesity and Related Disorders. London, UK (17–18 February, 2003).
   Google Scholar
• BRINER K, BURKHART JP, BURKHOLDER TP et al.: Synthesis of 4-benzofuran 7 yl 3 methyl tetrahydropyridines and piperidines as selective 5-HT2c receptor agonists for the treatment of obesity. 5th Winter Conference on Medicinal and Bioorganic Chemistry Steamboat Springs, USA (26–31 January, 2003).
   Google Scholar
• •This presentation described selective 5-HT2c agonists.
   Google Scholar
• BOS M, JENCK F, MARTIN JR et al: Synthesis, pharmacology and therapeutic potential of 10-methoxypyrazino[1,2-a]indoles, partial agonists at the 5-HT2c receptor. Eur: .1. Med. Chem. (1997) 32:253–261.
   Google Scholar
• ROEVER S, ADAMS D, BENTLEY JM et al.: Highly potent and selective 5-HT2c receptor agonists based on the pyrazino [1, 2-a]indole scaffold. Abstracts of Papers, 225th ACS National Meeting. New Orleans, USA (24–27 March, 2003).
   Google Scholar
• •This presentation described selective 5-HT2c agonists.
   Google Scholar
• HOFFMAN RL, ENNIS MD, GHAZAL NB et al.: The discovery and synthesis of a novel class of azepinoindoles with potent 5-HT2 affinity: identification, biological evaluation, and SAR of PNU-181731A. 28th National Medicinal Chemistry Symposium. San Diego, USA (8–12 June, 2002).
   Google Scholar
• WELMAKER GS, NELSON JA, SABALSKI JE et al: Synthesis and 5-hydroxytryptamine (5-HT) activity of 2,3,4, 4 a-tetrahydro-1H-pyrazino [1,2-a]quinoxalin-5-(61-4ones and 2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxalines. Bioorg. Med. Chem. Lett. (2000) 10:1991–1994.
   PubMed Web of Science ®Google Scholar
• ROSENZWEIG-LIPSON S, COUPET J,DUNLOP J, MCGONIGLE P: Antiobesity-like effects of the selective 5-HT2c agonist WAY-161503. FASEB.I. (2000) 14:A1321.
   Google Scholar
• ROBICHAUD AJ, CHEN W, MCCLUNG C et al.: Synthesis and biological evaluation of novel, selective 5-HT2c receptor agonists for the treatment of obesity. Abstracts of Paper.s 221st ACS National Meeting. San Diego, USA (1–5 April, 2001).
   Google Scholar
• •This presentation described selective 5-HT2c agonists.
   Google Scholar
• MCELROY J: Chronic effects of the 5-HT2c agonist IK-264 on food intake, body weight, and carcass composition in rats. International Conference on Obesity Sao Paulo, Brazil (25–29 August, 2002).
   Google Scholar
• ••This presentation provided interesting in vivo data on a promising, selective 5-HT2c agonist.
   Google Scholar
• NICHOLS NE SOBIE JL, CIMINI MG et al.: Amdolytic potential of PNU-57378E, a 5-HT2A/5-HT2c agonist: behavior in rodents. 32nd Annual Meeting of the Society of Neuroscience. Orlando, USA (2–7 November, 2002).
   Google Scholar
• SCHREIBER R, DE VRY J: Role of 5-HT2c receptors in the hypophagic effect of m-CPP, ORG 37684, CP-94,253 in the rat. Frog. Neuropsychopharmacol. Biol. Psychiatry (2002) 26:441–449.
   Google Scholar
• SCHREIBER R, SELBACH K, ASMUSSEN M, HESSE D, DE VRYJ: Effects of serotonin1j2receptor agonists on dark-phase food and water intake in rats. Pharmacol Biochem. Behav (2000) 67:291–305.
   Google Scholar
• SARGENT PA, SHARPLEY AL, WILLIAMS C et al.: 5-HT2c receptor activation decreases appetite and body weight in obese subjects. Psychopharmacology (Berl.) (1997) 133:309–312.
   PubMed Web of Science ®Google Scholar
• •This paper describes human clinical trial results with a 5-HT2c agonist.
   Google Scholar